Pramipexole versus ropinirole: Polysomnographic acute effects in restless legs syndrome

Movement Disorders

Volumn 26, Issue 5, 2011, Pages 892-895

  Manconi, Mauro ^a,b   Ferri, Raffaele ^c   Zucconi, Marco ^a   Oldani, Alessandro ^a   Giarolli, Laura ^a   Bottasini, Valentina ^a   Ferini Strambi, Luigi ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Ospedale Civico Lugano   (Switzerland)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Periodic leg movements; Polysomnography; Pramipexole; Restless legs syndrome; Ropinirole

Indexed keywords

PLACEBO; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; NAUSEA; NONREM SLEEP; PERIODIC LIMB MOVEMENT DISORDER; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; RESTLESS LEGS SYNDROME; SINGLE DRUG DOSE; SLEEP TIME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; PROSPECTIVE STUDIES; RESTLESS LEGS SYNDROME; STATISTICS AS TOPIC;

EID: 79955111102     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23543     Document Type: Article

References (15)

1. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-119.
2. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982; 39: 739.
3. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996; 19: 205-213.
4. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988; 24: 455-458.
5. Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006; 13: 1049-1065.
6. Manconi M, Ferri R, Zucconi M, et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med 2007; 8: 491-497.
7. Saletu B, Gruber G, Saletu M, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000; 41: 181-189.
8. American Academy of Sleep Medicine The International classification of sleep disorders. Diagnostic coding manual, Westchester, IL: American Academy of Sleep Medicine; 2005.
9. Manconi M, Ferri R, Feroah TR, Zucconi M, Ferini-Strambi L. Defining the boundaries of the response of sleep leg movements to a single dose of dopamine agonist. Sleep 2008; 31: 1229-1237.
10. Michaud M, Dumont M, Paquet J, Desautels A, Fantini ML, Montplaisir J. Circadian variation of the effects of immobility on symptoms of restless legs syndrome. Sleep 2005; 28: 843-846.
11. Ferri R, Manconi M, Arico D, et al. Acute dopamine-agonist treatment in restless legs syndrome: effects on sleep architecture and NREM sleep instability. Sleep 2010; 33: 793-800.
12. Saletu M, Anderer P, Saletu B, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 2000; 41: 190-199.
13. Linazasoro G. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 2004; 251: 335-339.
14. Quilici S, Abrams KR, Nicolas A, et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008; 9: 715-726.
15. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28: 1065-1078.